Is Alnylam Pharmaceuticals (ALNY) One of the Best Upside Stocks to Invest In Right Now?
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best upside stocks to invest in right now. On January 30, Bank of America lowered its price target on Alnylam to $462 from $529 while maintaining a Buy rating as part of the firm’s Q4 2025 small-to-mid cap biotech earnings preview.
On the same day, H.C. Wainwright also lowered its price target on Alnylam to $510 from $570 with a Buy rating. The firm reduced its estimates to reflect a more disciplined outlook for near-term growth and margins. Despite the adjustment, the firm sees compelling upside for the shares as the TTR franchise scales and the Alnylam 2030 strategy is implemented.
On January 27, Barclays analyst Eliana Merle assumed coverage of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) with an Overweight rating and a $527 price target. This initiation was part of a broader move in which Barclays began covering 12 biotech stocks and assumed coverage of 11 others, expressing a positive outlook on the industry for 2026. Merle noted that many biotech stocks remain undervalued and anticipates that significant tailwinds will benefit the sector.
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) discovers, develops, and commercializes therapeutics based on ribonucleic acid interference.
While we acknowledge the potential of ALNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Korean Analyst Expects XRP Channel to Push Prices to $5
VIPKevin Warsh Sworn in as Fed Chair, Putting Broad Pressure on Crypto Assets
1. Following Kevin Warsh's appointment as Fed chair, the Fed has shifted back toward a more conservative policy stance. His hawkish position — that rates should not be cut before inflation returns to target — has significantly pushed back market expectations for easing. Holding rates steady throughout the year has now become the market's base-case scenario, while tail risks of further hikes are also beginning to be priced in. Expectations for global liquidity are tightening, although total stablecoin market capitalization in crypto continues to reach new all-time highs, with USDGO emerging as one of the fastest-growing stablecoins. 2. 10-year sovereign bond yields across major developed economies surged sharply this week: Japan climbed above 2.75% to multi-decade highs, the U.S. reached 4.57%, the UK touched 4.92%, and Germany rose to 3.14%. Yield volatility reached 3–4 sigma levels during the week, marking one of the most extreme moves since the 2022 UK pension crisis. Risk-off sentiment strengthened significantly, with capital rotating away from risk assets and into defensive assets. 3. BTC declined 1.96% this week, but the OBV volume-price divergence strategy delivered the strongest performance with +4.46% alpha. The strategy focuses on price-volume divergence signals: when price makes a new range low but OBV does not confirm with a new low, it treats this as a sign that selling momentum is fading and executes a contrarian buy on the 5-minute timeframe. Assets to watch: BTC, ONDO, HYPE, NEAR, PDD (earnings on May 27), MRVL, CRM, DELL.
StablR loses parity after attack generates $13,5 million in fake news.
Nikkei 225 surpasses 65 points amid easing oil prices.
Trending news
MoreCrypto prices
More
